SCHEDULE: Invus Group Discloses 7.8% Stake in enGene Therapeutics
Schedule 13G Filing
Invus Public Equities, L.P. and affiliated entities have reported beneficial ownership of 7.8% of enGene Therapeutics Inc. common shares as of March 31, 2026.
Summary
- Invus Public Equities, L.P. and its affiliates (collectively, the "Reporting Persons") have disclosed beneficial ownership of 5,253,159 common shares of enGene Therapeutics Inc.
- This represents approximately 7.8% of the company's outstanding common shares as of March 31, 2026.
- The filing details the ownership structure, with Invus Public Equities holding 4,513,228 shares and Avicenna Life Sci Master Fund LP holding 739,931 shares.
- Control and beneficial ownership are attributed through various entities including Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., Avicenna Life Sci Master GP LLC, Ulys, L.L.C., and Mr. Raymond Debbane.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it is a standard disclosure of beneficial ownership and does not provide new operational or financial performance information.
Positives
- Significant investment by Invus Group indicates confidence in enGene Therapeutics' potential.
- The disclosure confirms a substantial institutional holding, which can be viewed positively by the market.
Future Outlook
The filing does not contain forward-looking statements or guidance. It is a disclosure of beneficial ownership.
Industry Context
StockSavvy.ai notes that significant stake disclosures by investment firms like Invus Group often signal a belief in the target company's growth prospects or potential for strategic change within the biotechnology sector.
Stakeholder Impact
- Shareholders may view the increased institutional ownership positively, potentially indicating greater market interest and stability.
- The disclosure provides transparency regarding significant ownership, which is important for all stakeholders.
Key Dates
| Date | Description |
|---|---|
| 03/03/2026 | Date of enGene Therapeutics' quarterly report on Form 10-Q providing outstanding share information. |
| 03/31/2026 | Date of Event Which Requires Filing of this Statement (ownership as of this date). |
| 05/05/2026 | Date of certification and signatures for the Schedule 13G filing. |
Keywords
enGene Therapeutics, Schedule 13G, Invus Group, beneficial ownership, common shares, institutional investor, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.